EntroGen has announced immediate availability of its KRAS/BRAF mutation panel as a comprehensive diagnostic predictor for efficacy of anti-EGFR monoclonal antibody therapies such as panitumumab (Vectibix) and cetuximab (Erbitux).
EntroGen’s panel is the only diagnostic tool available on the market that utilizes high sensitivity of allele-specific PCR methodology to target 11 mutations in KRAS gene (codons 11, 13 and 61) as well as an additional BRAF gene mutation (V600E). If at least one mutation among the 12 targets is detected, the patient would not benefit from the therapy as all of these mutations are activating the Ras-Raf-MAPK pathway.
EntroGen’s KRAS/BRAF mutation panel is available as RUO test for gel-electrophoresis and real-time PCR detection methods. This panel is the company’s latest addition to the line-up of pharmacogenomic tests with a mission to put simple, inexpensive, yet reliable genotyping assays into the hands of clinical laboratories, making pharmacogenomic testing more accessible to patients and their physicians.
For more information, please contact us at 818-342-2770 or visit us at www.EntroGen.com